60439-16-9

Basic information

• Product Name: (4-BROMO-BUTYL)-CYCLOHEXANE
• Synonyms: (4-BROMO-BUTYL)-CYCLOHEXANE;Cyclohexane, (4-bromobutyl)-
• CAS NO: 60439-16-9
• Molecular Formula: C₁₀H₁₉Br
• Molecular Weight: 219.16
• Mol File: 60439-16-9.mol

Chemical Properties

• Boiling Point: 244.1 °C at 760 mmHg
• Flash Point: 98.7 °C
• Appearance: /
• Density: 1.152 g/cm³
• CAS DataBase Reference: (4-BROMO-BUTYL)-CYCLOHEXANE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-BROMO-BUTYL)-CYCLOHEXANE(60439-16-9)
• EPA Substance Registry System: (4-BROMO-BUTYL)-CYCLOHEXANE(60439-16-9)

Safety Data

• Hazardous Substances Data: 60439-16-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(4-BROMO-BUTYL)-CYCLOHEXANE is used as a synthetic intermediate for the creation of more complex organic molecules, leveraging its reactive bromine atom to facilitate various chemical reactions in the synthesis process.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (4-BROMO-BUTYL)-CYCLOHEXANE serves as a key component in the development of new drugs, contributing to the molecular structures that possess therapeutic properties.
Used in Agrochemical Production:
(4-BROMO-BUTYL)-CYCLOHEXANE is utilized as a precursor in the synthesis of agrochemicals, playing a part in the formulation of products designed to enhance crop protection and yield.
Used in Industrial Chemical Production:
(4-BROMO-BUTYL)-CYCLOHEXANE is also employed in the manufacture of other industrial chemicals, where its unique structure and reactivity are harnessed to produce a variety of chemical products used across different sectors.
Safety Note:
Due to its flammable and toxic nature, (4-BROMO-BUTYL)-CYCLOHEXANE requires careful handling and proper storage measures to ensure the safety of individuals and the environment.

Upstream product

• 1647-26-3 1-bromo-2-cyclohexylethane 
• 4442-79-9 cyclohexylethan-1-ol 
• 110-52-1 1,4-dibromo-butane 
• 931-50-0 cyclohexylmagnesium bromide 
• 4441-57-0 4-cyclohexylbutan-1-ol 

Downstream Products

• 5962-88-9 5-cyclohexylvaleric acid 
• 265129-69-9 tert-butyl 2-(4-(2-(N-4-cyclohexylbutyl)aminoethyl)phenylthio)-2-methylpropanoate 
• 1402394-04-0 tert-butyl 2-(4-(2-(1-(4-cyclohexylbutyl)-3-(4-hydroxyphenyl)ureido)ethyl)phenylthio)-2-methylpropanoate 
• 1402394-01-7 C₃₄H₅₀N₂O₄S 
• 1402394-00-6 C₃₄H₅₀N₂O₄S 
• 1402393-99-0 C₃₄H₅₀N₂O₄S 
• 1310572-14-5 5-(4-cyclohexyl-butyl)-[2,2';5',2'';5'',2''']-quaterthiophene 
• 1310572-13-4 5,5'''-di(4-cyclohexyl-butyl)-[2,2';5',2'';5'',2''']quaterthiophene 
• 1367625-59-9 2-(4-cyclohexyl-butyl)-thiophene 
• 111025-97-9 <<1(R)-(cyclohexylpropyl)-2,3,3a,4,9,9a-hexahydro-5-methoxy-1H-(3aS,9aS)-benzinden-2(R)-yl>oxy>-(S)-α-methylbenzyl carbamate 
• 111025-97-9 <<1(S)-(cyclohexylpropyl)-2,3,3a,4,9,9a-hexahydro-5-methoxy-1H-(3aR,9aR)-benzinden-2(S)-yl>oxy>-(S)-α-methylbenzyl carbamate 
• 101691-70-7 <<(3-cyclohexylpropyl)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1H-benzinden-5-yl>oxy>acetic acid 
• 101691-70-7 <<1(R)-(3-cyclohexylpropyl)-2,3,3a,4,9,9a-hexahydro-2(R)-hydroxy-(3aS,9aS)-1H-benzinden-5-yl>oxy>acetic acid 
• 111137-57-6 <<1(S)-(3-cyclohexylpropyl)-2,3,3a,4,9,9a-hexahydro-2(S)-hydroxy-(3aR,9aR)-1H-benzinden-5-yl>oxy>acetic acid 

Relevant articles and documents

Synthesis, radiolabeling and initial in vivo evaluation of [ 11C]KSM-01 for imaging PPAR-α receptors

Peroxisome proliferator-activated receptor alpha (PPAR-α) is a ligand-activated nuclear receptor transcription factor that regulates the fatty acid β-oxidation. An in vitro assay identified the p-methoxy phenyl ureido thiobutyric acid derivative KSM-01 (IC50 = 0.28 ± 0.09 nM) having a higher affinity to activate PPAR-α than the PPAR-α agonist GW7647 (IC50 = 0.46 ± 0.19 nM). In this study, we report the synthesis and initial in vivo evaluation of [11C]KSM-01. The radiosynthesis was carried out by first alkylating the corresponding p-phenol precursor with [11C]MeI in DMF using NaOH, followed by deprotection of the t-butyl ester group by TFA, yielding [11C]KSM-01. SUV analysis of dynamic micro PET/CT imaging data showed that [11C]KSM-01 accumulation was ～2.0-fold greater in cardiac-specific PPAR-α overexpressing transgenic mice compared to wild-type littermates. The post-PET biodistribution studies were consistent with these results and demonstrated 2.5-fold greater radiotracer uptake in the heart of transgenic mice compared to the wild-type littermates. These results demonstrate the potential utility of PPAR-α agonists as PET radiopharmaceuticals.

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

Inhibitors of protein isoprenyl transferases

Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2is selected from (a) (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, and —P(W)RR3RR3′; R4is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7—L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene (k) a covalent bond, (l) and (m) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

2-Substituted histamines with G-protein-stimulatory activity

The cationic-amphiphilic 2-substituted histamines, 2-(2-chlorophenyl)histamine (2-ethanamine) and 2-(2-cyclohexylethyl)histamine, activate pertussis toxin-sensitive guanine nucleotide-binding proteins (G-proteins) of the Gi-subfamily by a receptor-independent mechanism.We studied structure-activity relationships of 2-substituted histamine derivatives for this G-protein activation using six known and 12 newly synthesized compounds.Elongation of the alkyl chain between imidazole and the ring system enhanced the potency and efficiency of substances in activating high-affinity GTP hydrolysis, ie the enzymatic activity of G-protein α subunits, in membranes of HL-60 leukemic cells.Cyclopentyl-, cyclohexyl- and norbornyl-substituted histamines were more effective and potent than phenyl-substituted histamines in mediating G-protein activation in HL-60 membranes and in activating reconstituted bovine brain Gi/Go-proteins.Our data show that the chain length and the type of ring system are important determinants for receptor-independent G-protein activation by 2-substituted histamines.With respect to histamine H1-receptors, most of the substances studied displayed weak antagonistic activity.

The Copper Halide-Catalyzed Mono-Substitution of Bromine in α,ω-Dibromoalkanes by Grignard Reagents. A Reinvestigation

α,ω-Dibromoalkanes have been converted into mono-bromides R(CH2)nBr by reaction with the Grignard compounds RMgBr in THF in the presence of 5 mol percent of copper(I)bromide.In contrast to what is suggested in the original literature, this method has a limited scope.

Interphenylene carbacyclin derivatives

A compound of the formula STR1 and intermediates useful in preparing same.

Liquid-Crystalline Solvents as Mechanistic Probes. 21. Control of Norrish II 1,4-Biradical Reactivity by the Phase and Molecular Dimensions of an Ordered Solvent

The fates of four triplet 1,4-biradicals (produced as Norrish II intermediates during the irradiations of n-decanophenone, 2-cyclohexyl-1-(4-ethylphenyl)-1-ethanone, 4-cyclohexyl-1-phenyl-1-butanone, and 5-cyclohexyl-1-phenyl-1-pentanone) have been explored in crystalline-, smectic B-like, nematic-, and isotropic-phase solutions of trans,trans-4'-n-butyl-4-carbonitrile (BCCN).The experimental probe is the ratio of elimination to cyclization products.The results indicate that the ordered phases of BCCN behave as a molecular ruler with regard to solute conformations; the micromorphology of each phase imposes a different set of constraints upon the shapes of the 1,4-biradicals.A rationalization for the seemingly bizarre phase-dependent changes in product ratios, based upon the shapes and labilities of the 1,4-biradicals, is presented.